M

Madras Diabetes Research Foundation | Chennai, India

Research site
(Unclaimed)
Location
No 4, Conran Smith Road, Gopalapuram, Chennai, Tamil Nadu, India
Site insights

Top conditions

Diabetes Mellitus (18 trials)

Type 2 Diabetes Mellitus (15 trials)

Obesity (3 trials)

Overweight (3 trials)

Cardiovascular Diseases (2 trials)

Top treatments

Semaglutide
Sugar
Metformin
LY3502970
Canakinumab
Ranolazine
Glucose
Vildagliptin
Orforglipron
Cagrilintide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

10 of 22
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL)

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Placebo (semaglutide)
Drug: Semaglutide

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two...

Enrolling
Type 2 Diabetes Mellitus
Drug: Cagrilintide
Drug: Semaglutide

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participan...

Active, not recruiting
Overweight
Type 2 Diabetes Mellitus
Drug: Cagrilintide
Drug: Placebo cagrilintide

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (m...

Enrolling
Type 2 Diabetes
Drug: Insulin glargine
Drug: IcoSema

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesit...

Enrolling
Chronic Kidney Disease
Obesity
Drug: Semaglutide
Drug: Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes a...

Enrolling
Type 2 Diabetes
Drug: Orforglipron
Drug: Placebo

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular...

Enrolling
Cardiovascular Disease
Drug: Semaglutide
Drug: Cagrilintide

Trial sponsors

Novo Nordisk logo

Novo Nordisk (8 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems